Abstract: A laryngeal nerve exciting system includes a collar holding a bridge, or a neckband, pressing soft tissue nerve exciters against a patient's neck providing a source of vibrations to stimulate the laryngeal nerve through the larynx. At least one exciter, and preferably two exciters, provide vibrations at preferably 70 Hz to 110 Hz and sufficiently strong to penetrate to the laryngeal nerve. The exciters may be held by the collar circling the neck, or by the neck band partially circling the neck. The therapy system includes a Personal Digital Assistant (PDA) and software which wirelessly connects, monitors, and triggers the device. The system may be used to treat dysphagia, chronic cough, and spasmodic dysphonia.

Abstract: A laryngeal nerve exciting system includes a collar holding a bridge, or a neckband, pressing soft tissue nerve exciters against a patient's neck providing a source of vibrations to stimulate the laryngeal nerve through the larynx. At least one exciter, and preferably two exciters, provide vibrations at preferably 70 Hz to 110 Hz and sufficiently strong to penetrate to the laryngeal nerve. The exciters may be held by the collar circling the neck, or by the neck band partially circling the neck. The therapy system includes a Personal Digital Assistant (PDA) and software which wirelessly connects, monitors, and triggers the device. The system may be used to treat dysphagia, chronic cough, and spasmodic dysphonia.

Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.

Abstract: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.

Abstract: Disclosed herein are biohybrid protein complexes capable of using light energy to photocatalyze the reduction of N2 into NH3. Also provided are methods of using biohybrid protein complexes to enzymatically reduce N2 to NH3 using light rather than chemical energy as the driving force. These methods may also include the production and isolation of ammonia, hydrogen or both.

Abstract: The track is elongate such that it extends along a longitudinal axis. The track comprises an alignment feature located at a predetermined alignment position along the longitudinal axis of the track. The alignment feature is configured to secure a partition support member at the alignment position when the partition support member is received by the track. The alignment feature comprises one of a projection or recess configured to engage with the other of a projection or recess of the partition support member.

Abstract: The present invention provides compositions and methods related to equine live-attenuated influenza vaccines. In one aspect, the invention relates to a composition comprising a multivalent equine live-attenuated influenza vaccine comprising a first live-attenuated influenza virus expressing one or more antigens of a clade 1 H3N8 equine influenza virus; and a second live-attenuated influenza virus expressing one or more antigens of a clade 2 H3N8 equine influenza virus, wherein the second live-attenuated influenza virus expresses HA, NA, or a combination thereof of A/equine/Lancashire/1/2016 H3N8.

Abstract: A software development system for generating a software application is provided. The software development system comprises a configuration file generator tool configured to: read a design model comprising a plurality of individual blocks with a specified data flow between the blocks, wherein each block has a defined behavioral expectation, wherein the design model is configured to cause a desired behavior for the software application when given a set of inputs. The configuration file generator tool is further configured to generate a configuration file, based on the design model, that identifies a plurality of preexisting, verified, and compiled/linked software code segments configured to perform mathematical and/or logical actions to cause the desired behavior for the software application.

Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.

Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.

Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.

Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.

Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.

Abstract: Disclosed herein are biohybrid protein complexes capable of using light energy to photocatalyze the reduction of N2 into NH3. Also provided are methods of using biohybrid protein complexes to enzymatically reduce N2 to NH3 using light rather than chemical energy as the driving force. These methods may also include the production and isolation of ammonia, hydrogen or both.

Abstract: The shopping cart desk is a portable desk that can be used with a shopping cart. The shopping cart desk can be stored and carried in a ring binder along with shopping coupons, frequent shopper/customer loyalty cards, paper, writing utensils, and other organizational accessories. For use, the shopping cart desk may be removed from the binder and legs may be deployed from within the desk. The desk may then be placed in or near the child seat of a shopping cart to provide a workspace and access to coupons.

Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A, L, and B are as defined herein, and methods of making and using the same.

Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.

Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A, L, and B are as defined herein, and methods of making and using the same.